Praxis Precision Medicines to Present at Upcoming Investor Conferences
Praxis Precision Medicines (NASDAQ: PRAX) announced participation in two investor conferences. Management will join the Guggenheim’s 4th Annual Immunology and Neurology Conference on November 14, 2022, at 10:45 a.m. ET, and the Piper Sandler 34th Annual Healthcare Conference on November 29, 2022, at 1:00 p.m. ET. Both events will feature live webcasts available on the company’s website, with replays accessible for 30 days post-event. Praxis is focused on developing therapies for CNS disorders using genetic insights, with a portfolio that includes four clinical-stage product candidates.
- None.
- None.
BOSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will participate in the following upcoming investor conferences:
- Guggenheim’s 4th Annual Immunology and Neurology Conference
- Fireside chat on Monday, November 14, 2022 at 10:45 a.m. ET
- Piper Sandler 34th Annual Healthcare Conference
- Fireside chat on Tuesday, November 29, 2022 at 1:00 p.m. ET
The events will be available via live webcast through the Events & Presentations page of the Investors + Media section of the company’s website at www.praxismedicines.com. Replays of the webcasts will be available on Praxis’ website for 30 days following the events.
About Praxis
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying insights from genetic epilepsies to both rare and more prevalent neurological disorders, using our understanding of shared biological targets and circuits in the brain. Praxis has established a broad portfolio with multiple programs, including product candidates across movement disorders, epilepsy and psychiatric disorders, with four clinical-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on LinkedIn and Twitter.
FAQ
When is Praxis Precision Medicines participating in investor conferences?
What is the stock symbol for Praxis Precision Medicines?
Where can I watch the webcasts for the conferences?
How long will the conference replays be available on Praxis' website?
What is the focus of Praxis Precision Medicines?
